Company intelligence / Profile preview
Defender Pharmaceuticals, Inc.
St. Louis, Missouri, United Statesdefenderpharma.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Defender's lead product DPI-386 (intranasal scopolamine gel) received a Complete Response Letter from the FDA in January 2024 for its NDA for prevention of motion sickness. The company had previously received priority review status for this application at the request of the U.S. Navy with a PDUFA date of January 26, 2024[4][8].
- Therapeutic areas
- OtherPsychiatryNeurologyInfectious Diseases
- Modalities
- Small moleculesVaccines
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
U.S. NavyNASAU.S. Army Medical Materiel Development Activity (USAMMDA)United States Naval Medical Research Unit (NAMRU-D)
Beyond the preview
Go deeper on Defender Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Defender Pharmaceuticals, Inc..